Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study

OBJECTIVE: To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS). METHODS: Patients (n = 232) were randomized to ofatumumab 3, 30, or 60 mg every 12 weeks, ofatum...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurology
Autors principals: Bar-Or, Amit, Grove, Richard A., Austin, Daren J., Tolson, Jerry M., VanMeter, Susan A., Lewis, Eric W., Derosier, Frederick J., Lopez, Monica C., Kavanagh, Sarah T., Miller, Aaron E., Sorensen, Per S.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5957306/
https://ncbi.nlm.nih.gov/pubmed/29695594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000005516
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars